Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20, 2017
Tian Zhang, MD

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

The STAMPEDE trial compared abiraterone acetate (Zytiga) to androgen deprivation therapy (ADT) in patients with metastatic and nonmetastatic prostate cancer.

Early disease-free survival benefits are being seen with abiraterone acetate in the nonmetastatic setting, suggesting it could be a marker for overall survival benefit, says Zhang.

x